Nuveen
GMAB icon

Nuveen’s Genmab GMAB Stock Holding History

Nuveen’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18M Buy
+42,948
New +$1.14M ﹤0.01% 2860
2022
Q2 		– Sell
-684,858
Closed -$24.8M – 3343
2022
Q1 		$24.8M Sell
684,858
-8,900
-1% -$305K 0.01% 1049
2021
Q4 		$27.4M Sell
693,758
-16,565
-2% -$691K 0.01% 1037
2021
Q3 		$31M Buy
710,323
+17,381
+3% +$780K 0.01% 967
2021
Q2 		$28.3M Buy
692,942
+192,502
+38% +$7.43M 0.01% 1103
2021
Q1 		$16.4M Sell
500,440
-8,060
-2% -$303K 0.01% 1463
2020
Q4 		$20.7M Sell
508,500
-80,256
-14% -$3M 0.01% 1247
2020
Q3 		$21.6M Buy
+588,756
New +$21.3M 0.01% 1012

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Nuveen's GMAB Position: Q2 2026 in Review

Nuveen opened a new position in Genmab (GMAB) in Q2 2026: 42,948 shares worth $1.18M. The stake represents ﹤0.01% of the portfolio and ranks #2860 among its holdings. This is a return to the name: Nuveen previously reported a position in GMAB as recently as Q1 2022.

Nuveen first reported a position in GMAB in Q3 2020 and has held it in 8 quarters since. The position peaked at $31M in Q3 2021. 291 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Nuveen held 42,948 shares of Genmab worth $1.18M as of Q2 2026.
  • Genmab was a new Nuveen position in Q2 2026.
  • Genmab made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2860 holding.
  • Nuveen first reported a position in Genmab in Q3 2020 and has held it in 8 quarters since.
  • Nuveen's Genmab position peaked at $31M in Q3 2021.
  • 291 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.